Literature DB >> 1967676

Pericardial disease and human immunodeficiency virus in Dar es Salaam, Tanzania.

J P Cegielski1, K Ramiya, G J Lallinger, I A Mtulia, I M Mbaga.   

Abstract

The number of patients admitted to Muhimbili Medical Centre, Tanzania, with pericardial effusions rose after the epidemic of acquired immunodeficiency syndrome (AIDS) began. To investigate a possible relation all patients with suspected pericardial disease admitted between Oct 1, 1987, and March 31, 1989, were studied. 28 of 42 patients (67%) were seropositive for human immunodeficiency virus (HIV). 28 of 39 patients (72%) with pericardial effusion were HIV-seropositive compared with 0 of 3 without effusion. More HIV-seronegative than HIV-seropositive patients were receiving antituberculous chemotherapy and had ascites at enrollment. Only 5 of 28 HIV-seropositive patients had clinical signs of AIDS. 9 of 14 HIV-seropositive patients tested had positive Mantoux tests. There were no significant differences between the HIV-seropositive and seronegative groups in the duration of symptoms, laboratory results, X-ray or ultrasound findings, frequency of tamponade, or mortality. 38 patients were treated for tuberculosis. Pericardial effusion is strongly associated with, and an early manifestation of, HIV infection in Tanzania.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Biology; Cardiovascular Effects; Delivery Of Health Care; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Examinations And Diagnoses; Health; Health Facilities; Hiv Infections; Hospitals; Incidence; Infections; Measurement; Physiology; Prevalence; Research Methodology; Research Report; Signs And Symptoms; Tanzania; Tuberculosis; Viral Diseases

Mesh:

Year:  1990        PMID: 1967676     DOI: 10.1016/0140-6736(90)90288-g

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

Review 1.  AIDS and the lung: update 1992. 2. Recent developments in the management of the pulmonary complications of HIV disease.

Authors:  D M Mitchell; R F Miller
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

Review 2.  Tuberculous pericarditis with and without HIV.

Authors:  Mpiko Ntsekhe; Bongani M Mayosi
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

3.  Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients.

Authors:  J G Hakim; I Ternouth; E Mushangi; S Siziya; V Robertson; A Malin
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

4.  Paracardial lipodystrophy versus pericardial effusion in HIV positive patients.

Authors:  T Neumann; A Chanbay; J Barkhausen; T Bartel
Journal:  Heart       Date:  2002-05       Impact factor: 5.994

Review 5.  Tuberculous pericarditis and AIDS: case reports and review.

Authors:  A Mastroianni; O Coronado; F Chiodo
Journal:  Eur J Epidemiol       Date:  1997-10       Impact factor: 8.082

Review 6.  Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa.

Authors:  Bongani M Mayosi
Journal:  Heart       Date:  2007-10       Impact factor: 5.994

7.  Cardiac involvement in HIV infected people in Yaounde, Cameroon.

Authors:  D Nzuobontane; K N Blackett; C Kuaban
Journal:  Postgrad Med J       Date:  2002-11       Impact factor: 2.401

Review 8.  HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment.

Authors:  M C Raviglione; J P Narain; A Kochi
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

Review 9.  Cardiac manifestations of HIV infection: an African perspective.

Authors:  Mpiko Ntsekhe; Bongani M Mayosi
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-23

10.  Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study of 157 patients in hospital in Zimbabwe.

Authors:  J G Hakim; J A Matenga; S Siziya
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.